Cell-mediated and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients
Abstract
Importance
Data on the humoral and cellular immune response to primary and booster SARS-CoV-2 vaccination in immunosuppressed patients is limited.
Objective
To determine humoral and cellular response to primary and booster vaccination in immunosuppressed patients and identify variables associated with poor response.
Design
Retrospective observational cohort study.
Setting
Large healthcare system in Northern California.
Participants
This study included patients fully vaccinated against SARS-CoV-2 (mRNA-1273, BNT162b2, or Ad26.COV2.S) who underwent clinical testing for anti-SARS-SoV-2 S1 IgG ELISA (anti-S1 IgG) and SARS-CoV-2 interferon gamma release assay (IGRA) from January 1, 2021 through November 15, 2021. A cohort of 18 immunocompetent volunteer healthcare workers were included as reference. No participants had a prior diagnosis of SARS-CoV-2 infection.
Exposure(s)
Immunosuppressive diseases and therapies.
Main Outcome(s) and Measure(s)
Humoral and cellular SARS-CoV-2 vaccine response as measured by anti-S1 IgG and SARS-CoV-2 IGRA, respectively, after primary and booster vaccination.
Results
496 patients (54% female; median age 50 years) were included in this study. Among immunosuppressed patients after primary vaccination, 62% (261/419) had positive anti-S1 IgG and 71% (277/389) had positive IGRA. After booster, 69% (81/118) had positive anti-S1 IgG and 73% (91/124) had positive IGRA. Immunosuppressive factors associated with low rates of humoral response after primary vaccination included anti-CD20 monoclonal antibodies ( P <.001), sphingosine 1-phsophate (S1P) receptor modulators ( P <.001), mycophenolate ( P =.002), and B cell lymphoma ( P =.004); those associated with low rates of cellular response included S1P receptor modulators ( P <.001) and mycophenolate ( P <.001). Of patients who responded poorly to primary vaccination, 16% (4/25) with hematologic malignancy or primary immunodeficiency developed a significantly increased humoral response after the booster dose, while 52% (14/27) with solid malignancy, solid organ transplantation, or autoimmune disease developed an increased response ( P =.009). Only 5% (2/42) of immunosuppressed patients developed a significantly increased cellular response following the booster dose.
Conclusions and Relevance
Cellular vaccine response rates were higher than humoral response rates in immunosuppressed individuals after primary vaccination, particularly among those undergoing B cell targeting therapies. However, humoral response can be increased with booster vaccination, even in patients on B cell targeting therapies.
Related articles
Related articles are currently not available for this article.